GlaxoSmithKline Pharmaceuticals Limited Recommends Common and Special Dividend for the Year Ended March 31, 2020; Appoints Sunita Maheshwari as an Additional Independent Director
Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, the company informed that Board of Directors of the Company at its meeting held on May 18, 2020 has appointed Dr. Sunita Maheshwari (Din: 01641411) as an Additional Independent Director of the Company for a term of five years with effect from 18 May 2020. Dr. Sunita Maheshwari is not related to any of the existing Directors of the Company and she is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority.